Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor
When combined with increased physical activity and a low-calorie diet, semaglutide (Wegovy) is indicated for weight management in patients with: Obesity (BMI of 30 kg/m or higher) Overweight (BMI of 27 kg/m or higher) with at least one weight-related health condition such as high cholesterol levels, hypertension (high blood pressure), heart disease, and type 2 diabetes Mechanism of action Semaglutide is a GLP-1 agonist that slows digestion, reduces appetite, and stabilizes blood sugar by working in the following ways: It mimics the action of glucagon-like peptide-1 in the lateral hypothalamus (hunger control centre), which suppresses appetite and gives you a feeling of satiety
Whether you are on your first week or your sixth month, the strategies here will help you preserve muscle, minimize side effects, and extract the maximum benefit from every dose
Timing tells us everything
Principles of Bioactive Lipid Signalling: Lessons From Sphingolipids